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Abstract
Ovarian Clear Cell Carcinoma (OCCC) is a distinctive subtype of Epithelial Ovarian Cancer (EOC). Compared with 
other subtypes of EOC, CCC has relatively poor in prognosis and bad outcome in current clinical management using 
maximal cytoreduction and platinum plus paclitaxel–based combined chemotherapy. Therefore, the investigation of 
molecular therapeutic approaches targeting at signaling pathways associated with chemoresistance is needed. This 
review describes some recent potential signaling pathway targets and also suggests putative small molecule kinase 
inhibitors as well as natural anti-cancer agents in combating this disease. 
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Ovarian cancer is the most lethal disease among all gynaecological 
malignancies. It can be categorized into three major groups according 
to the origins of the ovarian tumors: (1) epithelial tumors, (2) stromal 
tumors and (3) germ cell tumors. Among these three groups, Epithelial 
Ovarian Cancer (EOC) accounts for approximately 90% of ovarian 
malignancies and can be divided into four major histological subtypes 
based on morphological and appearance criteria: serous, mucinous, 
endometrioid and clear cell carcinoma. Each of these histologic 
subtypes is further subdivided into benign, borderline and malignant 
according to their malignant potential [1-3]. 
Ovarian Clear Cell Carcinoma (OCCC) is distinct 
histopathologically and clinically from the other EOC subtypes. This 
tumor has a high incidence at stage I and usually present as a large 
pelvic mass, rarely exist bilaterally, associated with endometriosis, 
hypercalcemia as well as thromboembolic vascular complications 
[4,5]. While the incidence of OCCC is not high and accounts 3.7-
12.1% of all EOC [4,6,7], patients with OCCC have a poorer prognosis 
and higher recurrences than patients with other EOC subtypes [8]. 
The recent clinical management of advanced EOC includes maximal 
cytoreduction and platinum plus paclitaxel–based combined 
chemotherapy. However, the survival rates of OCCC patients are 
much lower than other advanced EOC such as endometrial subtype 
[9,10]. The poor response of OCCC to platinum-based regimens may 
be due to the intrinsic chemo-resistance. Therefore, novel treatment 
approaches such as molecular-targeted therapies plus more effective 
combinations of new chemotherapeutic agents should be investigated 
in a prospective clinical trial in OCCC.
Although the underlying mechanisms of chemo-resistance in 
OCCC remain unclear, a growing body of reports has indicated that 
several signaling cascades aberrantly activated by genetic alteration are 
associated with poor response to platinum-based regimens in human 
cancers [11-16]. Among these signaling pathways, PI3K/AKT/mTOR is 
the most well-known signaling cascade involved in cisplatin/paclitaxel 
chemo-resistance of EOC [15-20]. Our laboratory has previously 
found that loss of MKP3 led to aberrant activation of AKT/ERK1/2 
activity [14], whereas overexpression of GRB7/GRB7v was remarkably 
associated with high-grade ovarian cancer including OCCC and 
increased AKT/ERK1/2 [21] signaling pathway. Moreover, activated 
AKT/ERK1/2 could upregulate the expression of crucial oncoprotein 
FOXM1 which was again significantly associated with high-grade 
tumors including OCCC [22]. Recent findings also indicated that the 
overexpressed Serine/Threonine Kinase PAK4 was also associated with 
OCCC and involved in a variety of tumorigenicity through activating 
c-Src and MEK1/ERK1/2 [23]. Furthermore, numerous studies have 
documented that mTOR, an essential modulator in cell proliferation, 
is frequently upregulated in human cancers including OCCC [24-29]. 
Therefore, this provides us an attractive target by exploring inhibitors 
in order to suppress its activity resulting in the elimination of cancer 
cells. Taken together, these reports have suggested that targeting 
PI3K/AKT/ERK/mTOR signaling cascade may be an effective novel 
therapeutic approach in OCCC.
Different from conventional anti-cancer drugs, the new trend of 
target-based therapeutics is the application of small molecule kinase 
inhibitors in inhibition of cancer cell growth and survival through de-
regulating of the aberrant activation of signaling activities. To date, 
more than 10 small molecule kinase inhibitors have been approved 
by US Food and Drug Administration (FDA) for clinical trial [30,31]. 
For examples, Raf265 (Novartis), PLX4032 (Roche), AZD6244 
(AstraZaneca), ARRY797 (Array BioPaherma) and Sorafenib (Bayer/
Onyx) etc. targeting Raf/MEK/ERK signaling cascade have been 
tested in different phases of clinical trials in a decade ago [32,33]. 
Recently, Temsirolimus (Torisel®) (Wyeth) and Everolimus (Afinitor®) 
(Novartis) (Merck) have been approved to treat patients with advanced 
and aggressive tumors through inhibiting mTOR mediated cell growth 
[34-36]. Moreover, Avastin® (bevacizumab), Tarceva (erlotinib) and 
MK-2206 are approved by FDA in clinical trial for advanced ovarian 
cancer with failing standard chempotherapy [36-38]. However, the 
concerning issues include the toxicity or side effects versus potency, 
as well as the specific inhibition versus multiple targeting when using 
these small molecule kinase inhibitors. 
Another approach is using the combination of current 
chemotherapeutic reagents and other anti-neoplastic agents which 
are specifically targeting P13K/AKT/ERK/mTOR signaling axis. For 
examples, Mabuchi et al. [25] have recently reported that the anticancer 
substance, Trabectedin or ET743 extracted from the sea squirt 
Ecteinascidia turbinate, exhibits high efficiency in the treatment of 
OCCC when in combination with Everolimus [39-41]. The combined 
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application of these drugs was able to sensitize OCCC cells to cisplatin- 
or paclitaxel-induced cell apoptosis in vitro and in vivo through 
inhibition of AKT/mTOR activity [39]. Apart from Trabectedin, an 
oral antidiabetic drug Metformin has recently been shown to have 
potent anti-cancer effects against a variety of human cancers [42-44]. 
Metformin is the biguanide derivative which has been generally used 
as the first-line drug for Type 2 diabetes [45,46]. But recent evidences 
from clinical and preclinical studies have shown that Metformin has 
anti-cancer functions. Clinically, retrospective data have found that 
diabetic patients with breast cancer receiving Metformin have better 
response under neoadjuvant chemotherapy [47]. This function is 
particularly obvious in Her2+ breast cancer patients [48]. Moreover, 
the combinational use of Metformin and temozolomide (TMZ) is 
useful to treat Glioblastoma multiforme (GBM) [49]. Mechanistically, 
the inhibition of cancer cell growth by Metformin is associated with 
indirect and direct effects. The indirect effect exerted by metformin 
is linked to the inhibition of treanscriptional activities of key 
gluconeogenesis genes which in turn elevating insulin sensitivity and 
decreasing blood glucose and insulin levels [50,51]. The direct effects 
of Metformin are through activation of AMP-activated protein kinase 
(AMPK) and inhibition of mammalian target of rapamycin (mTOR) 
which is an effector governing protein synthesis and gluconeogenesis 
[52,53]. The overall reduction of protein synthesis through inhibition 
of mTOR is the main mechanism of Metformin action in the inhibition 
of cancer cell growth. However, most cancer cells have constitutive 
action of phosphoinositide 3 kinase (PI3K) activity which leads to 
increased cell survival under chemotherapy treatment. Therefore, 
the co-treatment of PI3K inhibitor (LY294002) with Metformin can 
synergistically enhance cisplatin-induced cell apoptosis in ovarian 
cancer cells [54]. Together, these reports suggest that the use of 
natural anti-cancer agents is the alternative therapeutic approach in 
supplement to the current chemotherapeutic regimens against OCCC. 
In summary, although current treatment on OCCC always comes 
across of obstacles in clinical outcome, the exploration of molecular 
therapeutic approach using small molecular kinase inhibitors or even 
the intervention of natural anti-cancer agents will provide a new avenue 
in improving the efficiency of chemotherapy in this disease.
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